GlassScriptPhysician profile
Chase Beal
NPI 1548889983
$5,596.26
in general payments reported to CMS, 2019-2025
12 companies · $2,208 in 2025
The $2,208 reported for 2025 was more than what 81% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $3,388 · 2025: $2,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,252 · Travel and Lodging: $1,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,251.97 |
| Travel and Lodging | $1,344.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,683.21 | 2024-2025 | Intellis Adaptivestim, Synchromedii, Kyphon Express II Kyphopak Tray |
| Boston Scientific Corporation | $898.44 | 2024-2025 | Intracept, General - Pain Management, Wavewriter Alpha Prime 16 |
| Globus Medical, INC. | $813.00 | 2025 | Senza, Vyrsa V1 |
| Abbott Laboratories | $261.07 | 2025 | Proclaim |
| Averitas Pharma INC. | $236.61 | 2024-2025 | Qutenza |
| Spinal Simplicity, LLC | $232.47 | 2024 | Ha Minuteman G3-R |
| Curonix LLC | $168.41 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Ipsen Biopharmaceuticals, INC | $133.92 | 2024 | Dysport |
| Merz Pharmaceuticals, LLC | $74.21 | 2024 | Xeomin |
| Pacira Pharmaceuticals Incorporated | $35.75 | 2024-2025 | Exparel, Zilretta, Iovera |
| Vertex Pharmaceuticals Incorporated | $31.25 | 2024 | |
| Nalu Medical, INC. | $27.92 | 2025 | Nalu Neurostimulation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chase Beal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.